BMRN Financial Facts
Total operating expenses: 339.98MNET INCOME (LOSS) PER SHARE, BASIC: -0.26
See Full Income Statement
Accumulated deficit: -1.57B
Long-term investments: 362.96M
See Full Balance Sheet
BioMarin Pharmaceutical Inc. (BMRN) Earnings
|
Expand Research on BMRN
| Next EPS Date | 8/4/26 | EPS Growth Rate | -34.0% |
|---|---|---|---|
| Average EPS % Beat Rate | +71.5% | Revenue Growth Rate | +13.2% |
| Average % Move 1-Wk after EPS | -3.9% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
8/4/26  |
Q226 | N/A | $0.95 | N/A | N/A | $933.8M | = | N/A | N/A | ||
| 5/4/26 | Q126 | $0.76 | $0.74 | +$0.02 | $766M | $755.94M | = |  | | Details | |
| 2/23/26 | Q425 | $0.46 | $0.77 | -$0.31 | $875M | $829.31M | = | | | Details | |
| 10/27/25 | Q325 | $0.12 | -$0.08 | +$0.20 | $776M | $782.3M | = | | | Details | |
| 8/4/25 | Q225 | $1.44 | $0.83 | +$0.61 | $825M | $760.37M | = | | | Details | |
| 5/1/25 | Q125 | $1.13 | $0.70 | +$0.43 | $745M | $741.02M | = | | | Details | |
| 2/19/25 | Q424 | $0.92 | $0.55 | +$0.37 | $747M | $711.42M | = | | | Details | |
| 10/29/24 | Q324 | $0.91 | $0.53 | +$0.38 | $746M | $703.14M | = | | | Details |
